Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324945 · ClinicalTrials.gov registry record · NA
Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients
A NA study, sponsored by Rachel Miller.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03324945: Completed NA study, sponsored by Rachel Miller.
NCT03324945 is a NA study that has completed, run by Rachel Miller. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03324945, a NA study, has completed, sponsored by Rachel Miller.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Chemotherapy-induced cognitive impairment (CICI), also known as "chemobrain," is a spectrum of neurocognitive deficits experienced during and after the administration of chemotherapy for cancer. The incidence of CICI is significant, affecting anywhere from 25 to 75% of survivors, and the biologic basis is unknown. This novel study is designed to address the questions of incidence and biological cause for CICI, while gaining a better understanding of the structural and functional effects of chemotherapy on the brain.
Interventions
- BEHAVIORAL Neurocognitive assessments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2019-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03324945
The ClinicalTrials.gov registry entry for NCT03324945 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rachel Miller, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neurocognitive assessments is the first listed.
NCT03324945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03324945 about?
NCT03324945 is a clinical study titled "Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients". Chemotherapy-induced cognitive impairment (CICI), also known as "chemobrain," is a spectrum of neurocognitive deficits experienced during and after the administration of chemotherapy for cancer. The incidence of CICI is significant, affecting anywhere from 25 to 75% of survivors, and the biologic ba...
What is the current status of trial NCT03324945?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2016-08-01. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03324945?
The interventions under investigation include: Neurocognitive assessments (BEHAVIORAL).
Who is sponsoring clinical trial NCT03324945?
This trial is sponsored by Rachel Miller, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.